Clinical Trials Browser

Interventional × Renal Insufficiency × 1 year × Clear all

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT07489534 2026-03-24

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

Phase 2 Recruiting

25 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT06408597 2026-03-18

Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy

Phase NA Active not recruiting

90 enrolled

Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Renal Insufficiency, Acute Kidney Injury

NCT06142396 2026-03-12

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Phase EARLY_PHASE1 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT06623630 2026-03-11

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Phase 1 Recruiting

16 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Phase 2 Recruiting

20 enrolled

Renal Insufficiency

NCT07029503 2026-02-24

SCARF-1

Phase 2 Recruiting

40 enrolled

Lymphoid

Heart Failure, Lymphoma, Follicular, Renal Insufficiency, Chronic, Renal Insufficiency

NCT07154901 2026-02-24

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Phase 1 Recruiting

50 enrolled

Lymphoid

Lymphoma, Follicular, Renal Insufficiency

NCT04240054 2026-01-28

VICD

Phase 2 Recruiting

41 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT05443321 2026-01-23

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

Phase NA Enrolling by invitation

1,006 enrolled

GastrointestinalGenitourinary

Arrhythmias, Cardiac, Asthma, Cardiovascular Diseases, Gastrointestinal Diseases, Heart Failure, Hematologic Diseases, Infections, Kidney Diseases, Nervous System Diseases, Rheumatic Diseases, Shock, Urologic Diseases, Critical Illness, Renal Insufficiency

NCT04561362 2025-11-14

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Phase 1/2 Active not recruiting

329 enrolled

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Renal Insufficiency, Triple Negative Breast Neoplasms

NCT05992363 2025-07-24

TSTENT

Phase NA Recruiting

106 enrolled

Bites and Stings, Hydronephrosis, Neoplasms, Ureteral Obstruction, Renal Insufficiency

NCT01047735 2025-07-11

TRIABETES

Phase NA Active not recruiting

69 enrolled

Other

Behavior, Blindness, Body Weight, Cardiovascular Diseases, Death, Diabetes Mellitus, Diabetes Mellitus, Type 2, Digestive System Diseases, Disease, Hypertension, Inflammation, Insulin Resistance, Liver Diseases, Motor Activity, Myocardial Infarction, Neoplasms, Obesity, Obesity, Morbid, Weight Loss, Atherosclerosis, Renal Insufficiency, Non-alcoholic Fatty Liver Disease

NCT07053462 2025-07-08